HAIKOU, China, Nov. 6 After a reversemerger with Kun Run Biotechnology Limited, Aspen Racing Stables, Inc. (OTCBulletin Board: ASRS), announced today that pursuant to a Certificate ofAmendment to the Company's Certificate of Incorporation, as filed with theNevada Secretary of State on November 1, 2008, the name of the Company hasbeen changed to Kun Run Biotechnology, Inc. (hereafter "Kun Run" or the"Company").
The Company also announced that the new name will be effective on November6, 2008, its ticker symbol on the Over-the-Counter Bulletin Board ("OTC BB")will be changed to "KURU.OB"
About Kun Run Biotechnology, Inc.
Kun Run Biotechnology Ltd., together with its subsidiaries, engages inresearch, development, production and commercialization of self-brandedsynthesized polypeptide medicines. It uses pioneered solid phase peptidesynthesis (SPPS) and advanced purifying technology to produce varioustherapeutic polypeptide drugs, the most famous products of this company is"TP-5" which can efficiently regulate human's immune system in order todefense and cure malignant diseases. The company has two state-of-artmanufacturing plants and possesses one of the largest peptide synthesizecapacity across Asia.
Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Such statements are not guarantees of future performanceand are subject to risks and uncertainties that could cause the Company'sactual results and financial position to differ materially from those includedwithin the forward-looking statements. Forward-looking statements involverisks and uncertainties, including those relating to the Company's ability tointroduce, manufacture and distribute new drugs. Actual results may differmaterially from predicted results, and reported results should not beconsidered as an indication of future performance. The potential risks anduncertainties include, among others, the Company's ability to obtain rawmaterials needed in manufacturing, the continuing employment of key employees,the failure risks inherent in testing any new drug, the possibility thatregulatory approvals may be delayed or become unavailable, patent or licensingconcerns that may include litigation, direct competition from othermanufacturers and product obsolescence. More information about the potentialfactors that could affect the Company's business and financial results isincluded in the Company's filings, available via the United States Securitiesand Exchange Commission.
SOURCE Aspen Racing Stables, Inc.